When researchers want to understand why a peptide changes how much an animal eats, they often start in the brain. Specifically, they look at a region called the brainstem, which sits at the top of the spinal cord and acts as a relay station between the gut and higher brain centers. A recently published study in Nature Metabolism took this approach to an unusual scale, building what the authors describe as a cross-species atlas of more than 530,000 individual cells drawn from rat, mouse, and macaque brainstem tissue.
The peptide at the center of the investigation is cagrilintide, an amylin receptor agonist. Amylin is a hormone released by the pancreas alongside insulin, and it is known to influence feelings of fullness. Cagrilintide mimics that signal in a long-acting form. The researchers wanted to know not just that cagrilintide reduces food intake in animal models, but precisely which brain cells are responsible for carrying that effect.
Building a brainstem atlas
The research team used a technique called transcriptomics, which reads the active genes inside individual cells, to classify more than 530,000 cells from the caudal, or lower, brainstem of rats, mice, and macaques. By cataloguing which genes each cell expresses, scientists can sort cells into distinct populations the way a librarian sorts books by subject.
Across the three species, the atlas identified 80 distinct neuronal populations. The researchers then used spatial profiling to map exactly where each population sits within a structure called the dorsal vagal complex, or DVC, in the rat brain. The DVC is a small but densely wired hub that processes signals arriving from the digestive system and relays them to circuits involved in appetite and energy use.
Having a high-resolution map of the DVC across multiple species is significant because it allows scientists to ask whether a finding in a rodent is likely to translate to primates, including humans. If a specific neuron type appears in rats, macaques, and humans alike, it becomes a more credible candidate for explaining how a peptide might work broadly.
Two neuron populations that respond to cagrilintide
The atlas pointed to two neuron populations that express a gene called Calcr, which encodes the receptor that amylin and cagrilintide bind to. Both populations sit within the DVC, but in different sub-regions with different neighbors and, as the study shows, different roles.
The first population lives in a structure called the area postrema, a small zone that lacks the usual barrier separating the bloodstream from the brain. This makes it an ideal location for sensing hormones and peptides circulating in the blood. These area postrema neurons express Calcr alongside another gene, Ramp3, and the study found that a single dose of cagrilintide rapidly changed the pattern of gene activity inside them.
The second population lives a short distance away in the nucleus of the solitary tract, or NTS. These cells express Calcr alongside a gene called Prlh, which codes for a signaling molecule called prolactin-releasing hormone. This combination, referred to in the paper as Calcr/Prlh neurons, turned out to be the more consequential of the two.
Acute response versus long-term adaptation
The researchers made a careful distinction between what happens in the brain after a single dose of cagrilintide and what happens after prolonged treatment. This distinction reshaped the interpretation considerably.
To test the area postrema Calcr/Ramp3 neurons, the team used a technique called chemogenetics, which allows scientists to switch a targeted group of neurons on or off using a designer chemical. When they activated those area postrema neurons artificially in rats, there was no meaningful change in long-term food intake or body weight. The cells clearly responded to cagrilintide acutely at the gene-expression level, but artificially stimulating them alone did not reproduce the peptide's sustained effects on eating behavior.
For the NTS Calcr/Prlh neurons, the picture was different. Long-term cagrilintide treatment, rather than a single acute dose, caused a measurable increase in the expression of the Prlh gene inside these cells. The longer the exposure, the more this adaptation became apparent, suggesting these neurons are particularly relevant to the sustained rather than the immediate effects of the peptide.
The Prlh knockdown experiment
To confirm that Calcr/Prlh neurons are genuinely necessary for cagrilintide's effects and not just coincidentally active, the researchers performed a knockdown experiment. They used a molecular tool to selectively reduce Prlh expression specifically within DVC neurons in rats, then treated those animals with cagrilintide and measured what happened.
When DVC Prlh was silenced, cagrilintide largely stopped working. The reduction in food intake and body weight that the peptide normally produces in rats was significantly blunted. This finding positions Calcr/Prlh neurons not as passive bystanders but as an essential link in the chain connecting cagrilintide to its downstream effects on energy balance.
The researchers also ran the same knockdown experiment using a different peptide, semaglutide, which works through a completely separate receptor. Knocking down DVC Prlh had no meaningful effect on semaglutide's actions. This double dissociation provides strong evidence that the Calcr/Prlh pathway is specific to amylin receptor signaling rather than a general appetite-control hub.
Cross-species conservation
One of the study's most notable findings is that Calcr/Prlh neurons appear to be conserved across species. The atlas identified analogous populations in mice, macaques, and, based on the transcriptomic signatures, in human brainstem tissue as well.
Conservation across species matters for research because it increases confidence that mechanisms observed in rodent experiments might be relevant in humans. The area postrema Calcr/Ramp3 neurons were also identified across the species studied, reinforcing the cross-species validity of the broader atlas. However, the functional data specifically pointed to the NTS Calcr/Prlh population as the critical mediator of long-term energy balance effects.
The researchers are careful to note that the atlas itself is a resource, not a clinical conclusion. It provides a detailed reference map that other scientists can use to design and interpret future studies on brainstem circuits involved in appetite, satiety, and metabolic regulation.
What the study adds to the field
Prior to this work, the brainstem's role in mediating amylin receptor agonist effects was understood only in broad strokes. It was known that the DVC is an important site of action for amylin-related peptides, but the specific cell populations responsible had not been mapped at single-cell resolution across species.
By combining the large-scale transcriptomic atlas with spatial profiling, chemogenetics, and targeted gene knockdown, the research team was able to move from correlation to a more mechanistic understanding. The literature now has a named, spatially located, cross-species conserved neuron population, Calcr/Prlh cells in the NTS, that appears to be necessary for the long-term energy balance effects of amylin receptor agonism.
Early data from the study also raises questions worth exploring in future work. Why does the area postrema respond so quickly to cagrilintide at the gene level, yet artificial activation of those neurons does not replicate the peptide's behavioral effects? One possibility the authors raise is that the area postrema neurons serve a different function, perhaps in sensing the peptide's presence and relaying information to adjacent structures, rather than directly driving the reduction in food intake. Resolving that question will likely require additional experiments in both rodents and primates.
